Avantor, Inc.
For the period ended Mar 31, 2026. Filed Apr 29, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 29, 2026
AVTR$15.91+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Glossaryii
Glossary
| Description | |
| the Company, we, us, our | Avantor, Inc. and its subsidiaries |
|---|---|
| Adjusted EBITDA | our earnings or loss before interest, taxes, depreciation, amortization and certain other adjustments |
| Adjusted Operating Income | our earnings or loss before interest, taxes, amortization and certain other adjustments |
| AOCI | accumulated other comprehensive income or loss |
| ASU | Accounting Standards Update |
| CODM | chief operating decision maker |
| EURIBOR | the basic rate of interest used in lending between banks on the European Union interbank market |
| FASB | the Financial Accounting Standards Board of the United States |
| Fluid Handling | Single use systems and integrated solutions used to support the production of biologic drugs and therapies |
| GAAP | United States generally accepted accounting principles |
| Long-term | period other than short-term |
| NuSil | Ultra-high purity medical and aerospace grade silicone formulations |
| OCI | other comprehensive income or loss |
| Process Chemicals | Process ingredients and excipients used to support the production of biologic drugs and therapies |
| Research & Specialty Chemicals | Proprietary formulated solutions for semiconductor manufacturing and proprietary chemicals for healthcare, biopharma, diagnostic, and industrial applications |
| RSU | restricted stock units represent awards that will vest annually and awards that contain performance and market conditions |
| SEC | the United States Securities and Exchange Commission |
| Services | Services and products designed to optimize and manage end-to-end laboratory operations for customers across industries such as biopharma, education, industrial, and technology sectors |
| SG&A expenses | selling, general and administrative expenses |
| Short-term | period less than a year from the reporting date |
| SOFR | secured overnight financing rate |
| Specialty procurement | product sales related to customer procurement services |
| VWR Channel | Mission-critical consumables, chemicals, and equipment and instrumentation used by scientists in their labs |
ii
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.